Abietane-type diterpenes from Torreya grandis aril and their preparation and application
By extracting and isolating the rosin alkyl diterpenoid compounds Torregrandin K and Torregrandin L from the pseudo-seed coat of Chinese torregas, the problems of waste disposal and resource utilization of traditional Chinese medicine processing are solved, and the preparation and anti-inflammatory activities of high-purity compounds are achieved. New directions for the development of anti-inflammatory drugs.
Patent Information
- Application Number
- CN202410511616.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-26
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-04-26
AI Technical Summary
The waste generated during traditional Chinese medicine processing, especially the fake seed coat of Chinese torreya, has not been effectively utilized, resulting in waste of resources and environmental pollution.
By extracting and isolating two novel rosin alkyl diterpene compounds Torregrandin K and Torregrandin L from the pseudo-seed coat of Torregrandin, using organic solvent leaching and column separation techniques, high-purity compounds were prepared and their resistance was explored. Inflammation drugs.
It has successfully obtained a high-purity rosin alkyl diterpene compound, which has significant in vitro anti-inflammatory activity, can effectively inhibit the expression of inflammatory factors IL-1β or IL-6, provides a new direction for the development of anti-inflammatory drugs, and solves the problem of Torreya Problems of processing waste disposal.
Smart Images

Figure SMS_1 
Figure SMS_4 
Figure SMS_5
Abstract
Description
(I) Technical field
[0001] The invention relates to the field of traditional Chinese medicine extraction, and specifically to abietane-type diterpenoid compounds and a preparation method thereof and an application thereof in anti-inflammatory aspects. (II) Background technology
[0002] Traditional Chinese medicine waste refers to a large number of non-medicinal parts and discarded tissues or organs generated during the process of picking and processing traditional Chinese medicine. The production and processing of large quantities of traditional Chinese medicines will inevitably generate a large amount of waste. These wastes are usually directly processed, resulting in resource waste and ecological environmental pollution. Therefore, the rational and effective development of traditional Chinese medicine waste is expected to achieve the resource utilization of traditional Chinese medicine waste and build a green, low-carbon and circular development of traditional Chinese medicine system. The non-medicinal parts of traditional Chinese medicine contain rich chemical components. By extracting, separating, purifying and evaluating the biological activity of these chemical components, their potential utilization value can be explored.
[0003] Torreya grandis is the dried mature seed of the Taxaceae plant Torreya grandis, which is rich in protein and various trace elements. After being fried and processed, Torreya grandis is a precious dried fruit. Torreya grandis aril is a layer of fleshy seed coat wrapped around the Torreya grandis, accounting for about 50% of the weight of Torreya grandis fruit. It is a waste in the Torreya grandis processing process and is often directly piled up on the roadside as waste. It has a strong odor, causing great waste of resources and environmental pollution. (III) Summary of the invention
[0004] The present invention aims to provide a rosinane-type diterpenoids derived from Torreya grandis aril and the preparation and application thereof, which not only solves the problem of waste disposal in Torreya grandis processing, but also provides a new anti-inflammatory drug.
[0005] The technical solution adopted by the present invention is:
[0006] In the first aspect, the present invention provides two novel abietane-type diterpenoid compounds derived from Torreya grandis aril, respectively named Torregrandin K and Torregrandin L; the molecular formula of Torregrandin K is C 20 H 30 O5, the structural formula is shown in formula (I); the molecular formula of Torregrandin L is C 21 H 32 O3, the structural formula is shown in formula (II);
[0007]
[0008] In a second aspect, the present invention further provides a method for preparing the abietane-type diterpenoid compound, the method being carried out according to the following steps:
[0009] 1) taking Torreya grandis aril, air-drying it naturally, crushing it, extracting it with an organic solvent, and recovering the solvent under reduced pressure to obtain a crude extract; the organic solvent is 95% ethanol, methanol or acetone, preferably 95% ethanol;
[0010] 2) suspending the crude extract with water, extracting with an organic solvent, collecting the organic phase, and recovering the solvent under reduced pressure to obtain an extract extract; the organic solvent is petroleum ether, ethyl acetate, dichloromethane or chloroform, preferably ethyl acetate;
[0011] 3) dissolving the extract from step 2) in methanol, and performing gradient elution on an MCI CHP20P column using methanol / water in a volume ratio of 10:90 to 100:0 as an eluent, with 4 column volumes for each gradient elution, and performing thin layer chromatography detection using dichloromethane / methanol in a volume ratio of 20:1, and collecting components with Rf values of 0.4-0.5 and 0.5-0.6 respectively;
[0012] 4) The component with an Rf value of 0.5-0.6 obtained in step 3) was dissolved in methanol, and then gradient eluted on a silica gel (200-300 mesh) column with a petroleum ether (boiling range 60-90° C.) / acetone mixed solvent in a volume ratio of 6:1 to 3:1 as an eluent, each gradient elution was 4 column volumes, and thin layer chromatography was performed with dichloromethane / methanol in a volume ratio of 20:1 to collect the component with an Rf value of 0.5; finally, the component with an Rf value of 0.5 was purified by semi-preparative liquid chromatography with methanol / water in a volume ratio of 65:35 as a mobile phase, and the component with a retention time of 14 min was collected, and the solvent was removed by concentration under reduced pressure to obtain the compound represented by formula (I).
[0013] 5) The component with an Rf value of 0.4-0.5 obtained in step 3) is dissolved in methanol, and then gradient eluted on a silica gel (100-200 mesh) column with petroleum ether / ethyl acetate in a volume ratio of 6:1 to 2:1 as an eluent, each gradient elution is 4 column volumes, and thin layer chromatography is performed with petroleum ether / acetone in a volume ratio of 2:1 to collect components with an Rf value of 0.5-0.6; finally, the component with an Rf value of 0.5-0.6 is subjected to ODS C-18 column chromatography with a methanol / water mixed solvent in a volume ratio of 50:50 to 75:25 as an eluent, and thin layer chromatography is performed with petroleum ether / acetone in a volume ratio of 2:1 to collect components with an Rf value of 0.5, and the solvent is removed by concentration under reduced pressure to obtain the compound represented by formula (II).
[0014] Furthermore, in step 1), the volume amount of the organic solvent is 2-5 mL / g based on the weight of the Torreya grandis aril powder; the extraction is performed at least 3 times, and each extraction time is 3-5 days.
[0015] Furthermore, in step 2), the volume of water used is 2-5 mL / g based on the weight of the crude extract; the volume ratio of the organic solvent to water is 1:0.5-2; and the extraction is performed 3-5 times.
[0016] Further, in step 3), the volume of methanol used is 5 mL / g based on the mass of the extract; the elution conditions of the MCICHP20P column chromatography are: gradient elution using a methanol / water mixed solvent with a volume ratio of 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, and 100:0 as the eluent.
[0017] Further, in step 4), the volume of methanol used is 6-7 mL / g based on the mass of the component with an Rf value of 0.5-0.6; the elution conditions of the silica gel (200-300 mesh) column chromatography are: gradient elution using a petroleum ether / acetone mixed solvent with a volume ratio of 6:1, 4:1, and 3:1 as the eluent.
[0018] Further, in step 5), the volume of methanol is 6-7 mL / g based on the mass of the component with an Rf value of 0.4-0.5; the elution conditions of the silica gel (100-200 mesh) column chromatography are: gradient elution with a petroleum ether / ethyl acetate mixed solvent with a volume ratio of 6:1, 4:1, 3:1, and 2:1 as the eluent; the elution conditions of the ODS C-18 column chromatography are: isocratic elution with a methanol / water mixed solvent with a volume ratio of 50:50, 55:45, 60:40, 65:35, 70:30, and 75:25 as the eluent.
[0019] In a third aspect, the present invention also provides the use of the abietane-type diterpenoid compound in the preparation of an inflammatory factor inhibitor, wherein the inflammatory factor is IL-1β or IL-6.
[0020] In a fourth aspect, the present invention also provides the use of the abietane-type diterpenoid compound in the preparation of anti-inflammatory drugs.
[0021] Compared with the prior art, the present invention has the following beneficial effects: (1) The present invention obtains two novel abietane-type diterpenoid compounds, Torregrandin K and Torregrandin L, from the aril of Torreya grandis through simple processes such as organic solvent extraction and chromatographic column separation. The preparation method is simple and rapid, and the obtained compounds have high purity. (2) The abietane-type diterpenoid compounds provided by the present invention have good in vitro anti-inflammatory activity, can effectively inhibit the expression of inflammatory factors IL-1β or IL-6, and can be used in the development of anti-inflammatory drugs. Using such compounds as lead compounds and carrying out structural optimization is of great significance for the development of new anti-inflammatory drugs. (IV) Description of the drawings
[0022] Figure 1 is the hydrogen spectrum of compound 1.
[0023] Figure 2 is the carbon spectrum of compound 1.
[0024] Figure 3 is the DEPT spectrum of compound 1.
[0025] Figure 4 is the HSQC spectrum of compound 1.
[0026] Figure 5 is compound 1 1 H- 1 H COSY spectrum.
[0027] Figure 6 is the HMBC spectrum of compound 1.
[0028] Figure 7 is the NOESY spectrum of compound 1.
[0029] Figure 8 is the infrared spectrum of compound 1.
[0030] Fig. 9 This is the high-resolution mass spectrum of compound 1.
[0031] Fig.10 The effect of compound 1 on the mRNA expression level of inflammatory factors in LPS-induced RAW 264.7 cells.
[0032] Fig.11 is the hydrogen spectrum of compound 2.
[0033] Fig.12 is the carbon spectrum of compound 2.
[0034] Fig.13 is the DEPT spectrum of compound 2.
[0035] Fig.14 is the HSQC spectrum of compound 2.
[0036] Fig.15 It is compound 2 1 H- 1 H COSY spectrum.
[0037] Fig.16 is the HMBC spectrum of compound 2.
[0038] Fig.17 is the NOESY spectrum of compound 2.
[0039] Fig.18 is the infrared spectrum of compound 2.
[0040] Fig.19 This is the high-resolution mass spectrum of compound 2.
[0041] Fig. 20 is the UV spectrum of compound 2.
[0042] Fig.21 is the electronic circular dichroism (CD) spectrum of compound 2.
[0043] Fig. 22 There are two possible relative configurations of compound 2.
[0044] Fig.23 Comparison of the experimental NMR chemical shifts of compound 2 with the calculated shifts of Isomer 1 and Isomer 2.
[0045] Fig.24 The effect of compound 2 on the mRNA expression level of inflammatory factors in LPS-induced RAW 264.7 cells. (V) Specific implementation methods
[0046] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto:
[0047] The room temperature described in the present invention refers to 25-30°C.
[0048] Example 1 Isolation and purification of compounds
[0049] (1) Preparation of crude extract: The fruits of Torreya grandis (T. grandis) collected from Fengqiao Town, Zhuji City, Zhejiang Province were removed from the seeds, and the arils were retained. The fruits were naturally air-dried and then crushed to obtain aril crushed products. 2 kg of aril crushed products were extracted with 30 L of 95% ethanol at room temperature for 4 days, and the extraction was repeated 3 times. The extracts were combined and concentrated under reduced pressure until no liquid flowed out or no ethanol smell was found, to obtain 485.2 g of crude extract.
[0050] (2) Extraction: 485.2 g of the crude extract was suspended in 2 L of water and extracted with ethyl acetate, 2 L each time, for a total of 3 extractions; the ethyl acetate phases were combined and the solvent was recovered under reduced pressure to obtain 39 g of ethyl acetate extract.
[0051] (3) MCI CHP20P column chromatography: The ethyl acetate extract (39 g) was dissolved in 0.2 L of methanol and initially separated by MCI CHP20P (7 cm in diameter and 30 cm in height) column chromatography. Gradient elution was performed using a methanol / water mixed solvent with a volume ratio of 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, and 100:0 as the eluent. Each gradient elution was 4 column volumes (2 L). Using thin layer chromatography (developing solvent: dichloromethane / methanol 20:1, v / v) as a guide, component A with an Rf value of 0.4-0.5 and component B with an Rf value of 0.5-0.6 were collected.
[0052] (4) Compound 1: Component B (1.5 g) was dissolved in 10 mL of methanol and separated by silica gel column chromatography (200-300 mesh, 4 cm in diameter and 30 cm in height), using a gradient elution of petroleum ether (boiling range 60-90° C.) / acetone in a volume ratio of 6:1, 4:1, and 3:1, with 4 column volumes for each gradient elution. Using thin layer chromatography (developing solvent: dichloromethane / methanol 20:1, v / v) as a guide, the component B1 with an Rf value of 0.5 was combined. Component B1 (295.9 mg) was purified by semi-preparative liquid phase separation, using methanol / water in a volume ratio of 65:35 as an eluent for isocratic elution, and the fraction with a retention time of 14.0 min was collected and concentrated under reduced pressure to remove the solvent to obtain compound 1 (8.0 mg).
[0053] (5) Compound 2: Component A (3.0 g) was dissolved in 20 mL of methanol and separated by silica gel column chromatography (100-200 mesh, 4 cm in diameter and 30 cm in height) using a gradient elution with petroleum ether / ethyl acetate in a volume ratio of 6:1, 4:1, 3:1, and 2:1. Each gradient elution was performed over 4 column volumes. Component A1 with an Rf value of 0.5-0.6 was collected using thin layer chromatography (development was petroleum ether / acetone 2:1, v / v) as a guide. Component A1 (39.5 mg) was then separated by ODS C-18 column chromatography (2.5 cm in diameter and 30 cm in height), with 4 column volumes of gradient elution each time, using methanol / water in a volume ratio of 50:50, 55:45, 60:40, 65:35, 70:30, and 75:25 as the eluent for gradient elution, guided by thin layer chromatography (developing with petroleum ether / acetone 2:1, v / v), and the spots with an Rf value of approximately 0.5 were combined, and the solvent was removed by concentration under reduced pressure to obtain compound 2 (32.5 mg).
[0054] Example 2 Compound Structure Identification
[0055] 1. Structural identification of compound 1
[0056] Compound 1 was subjected to hydrogen spectrum, carbon spectrum, DEPT spectrum, HSQC spectrum, 1H- 1 H COSY spectrum, HMBC spectrum, NOESY spectrum, infrared spectrum, high-resolution mass spectrometry detection, the results are shown in Figure 1-Figure 9 Compound 1 is a yellow oil, and high-resolution mass spectrometry gives a quasi-molecular ion peak m / z: 373.1974 [M+Na] + (calcd.for C 20 H 30 NaO5, 373.1985), and its molecular formula was determined to be C by combining hydrogen and carbon spectra. 20 H 30 O5, unsaturation is 6. Optical rotation The hydrogen spectrum shows four groups of methyl proton signals [(δ H 1.42,3H,s,H3-16),(δ H 1.22,3H,s,H3-17),(δ H 1.18,3H,s,H3-19),(δ H 1.02,3H,s,H3-20)], two groups of oxygen-linked methine proton signals [(δ H 3.61,1H,brs,H-12)(with oxygen), (δ H 4.39,1H,s,H-14)(with oxygen)]. Carbon spectrum and DEPT spectrum showed 20 carbon atoms, including 1 carboxyl carbon [δ C 183.1(C-18)], 4 methyl carbons [δ C 27.7 (C-16), 25.2 (C-17), 16.6 (C-19), 20.5 (C-20)], 6 methylene carbons [δ C 36.29 (C-1), 18.4 (C-2), 36.30 (C-3), 21.1 (C-6), 28.0 (C-7), 23.3 (C-11)], 3 methine carbons [δ C 45.6 (C-5), 57.8 (C-12) (with oxygen), 68.6 (C-14) (with oxygen)] and 6 quaternary carbons [δ C 47.3 (C-4), 126.0 (C-8), 135.8 (C-9), 37.0 (C-10), 65.7 (C-13) (with oxygen), 71.4 (C-15) (with oxygen)]. The above data have typical characteristics of abietane-type diterpenes, indicating that compound 1 is abietane-type diterpenes. In addition, δ C The carbon signals at 57.8 (C-12), 65.7 (C-13), 68.6 (C-14), and 71.4 (C-15) indicated that compound 1 was highly oxidized.
[0057]
[0058] Formula (A) is the structure of compound 1; Formula (B) is the main 1 H- 1 H COSY and HMBC correlation; formula (C) is the main NOE correlation of compound 1.
[0059] A careful comparison and analysis revealed that the NMR data of compound 1 and holophyllin N (J.Nat.Prod., 2016, 79, 387-394) were very similar. The main difference between the two is that a group of methine signals in holophyllin N [(δ C 30.6(C-15);(δ H 2.15, sept, J = 7.0, H2-15)] is a group of sp 3 Hybridized oxygen-linked quaternary carbon (δ C 71.4). In the HMBC spectrum, the oxygen-linked quaternary carbon (δ C 71.4) and C-16 (δ C 27.7), C-17(δ C 25.2), indicating that the oxygen-linked quaternary carbon is located at C-15. H 1.42,s,H3-16),H-17(δ H 1.22,s,H3-17) and C-13(δ C 65.7) further confirmed that it was located at the C-15 position. Combining the molecular formula and unsaturation, it can be inferred that there is a hydroxyl group at the C-15 position of compound 1. Through comprehensive analysis of the two-dimensional spectrum of compound 1, its planar structure was finally determined to be a rosinane-type diterpene with an epoxy group on the C ring.
[0060] The relative configuration of compound 1 was determined mainly by NOESY spectrum analysis. In abietane-type diterpenes, the A / B rings are trans-coupled, that is, H-5 is in α configuration and Me-20 is in β configuration. In the NOESY spectrum of compound 1, Me-19 (δ H 1.18) / Me-20(δ H 1.02), indicating that Me-19 is in β configuration. H 1.02) / H a -11(δ H 2.28) / H-12(δ H 3.60), H-12(δ H 3.60) / H-17(δ H 1.22), H-14(δ H4.39) / H-16(δ H 1.42) showed that the NOE correlation signals between OH-14 and the epoxy groups at positions 12 and 13 were in α configuration. Therefore, the relative configuration of compound 1 was determined to be 4R*, 5R*, 10S*, 12S*, 13R*, 14R*. Based on the above analysis, compound 1 was resolved to have the structure shown in formula (I) and was named Torregrandin K.
[0061] Table 1 NMR data of compound 1 (CDCl3; hydrogen spectrum and carbon spectrum were measured at 600 and 100 MHz respectively)
[0062]
[0063] 2. Structural identification of compound 2
[0064] Compound 2 was subjected to hydrogen spectrum, carbon spectrum, DEPT spectrum, HSQC spectrum, 1 H- 1 H COSY spectrum, HMBC spectrum, NOESY spectrum, infrared spectrum, high-resolution mass spectrum, ultraviolet spectrum, CD spectrum detection, the results are shown in Figure 11-Figure 23 Compound 2 is a colorless oil, and high-resolution mass spectrometry gives a quasi-molecular ion peak m / z: 331.2260 [MH] - (calcd.for C 21 H 31 O3,331.2279), and its molecular formula was determined to be C by combining hydrogen and carbon spectra. 21 H 32 O3, unsaturation is 6. Optical rotation The hydrogen spectrum showed five groups of methyl proton signals [(δ H 3.26,3H,s,H3-21)(with oxygen);(δ H 1.81,3H,s,H3-16);(δ H 1.78,3H,s,H3-17);(δ H 1.19,3H,s,H3-19);(δ H 0.76, 3H, s, H3-20)], 1 group of oxygen-linked methine proton signals (δ H 4.35, 1H, brs, H-12) and a group of olefin methine proton signals (δ H 6.05, 1H, s, H-14). Carbon spectrum and DEPT spectrum showed that compound 2 contained 21 carbon atoms, including 5 methyl carbon atoms [δ C 20.6(C-16);δ C 20.2(C-17);δ C 16.9(C-19);δ C15.0(C-20);δ C 55.3 (C-21)], six methylene carbons [δ C 18.2(C-2);δ C 38.4(C-1);δ C 37.05(C-3);δ C 24.8(C-6);δ C 35,2(C-7);δ C 26.9 (C-11)], four methine carbons [δ C 48.6(C-5);δ C 46.9(C-9);δ C 73.6(C-12)(with oxygen);δ C 119.5(C-14)] and six quaternary carbons [δ C 47.3(C-4);δ C 138.7(C-8);δ C 37.13(C-10);δ C 127.8(C-13);δ C 128.9(C-15);δ C 184.3 (C-18)]. The above data have typical characteristics of abietane-type diterpenes, suggesting that compound 2 is abietane-type diterpenes. C The carbon signals at 138.7 (C-8), 127.8 (C-13), 119.5 (C-14), and 128.9 (C-15) indicate the presence of a double bond in compound 2.
[0065]
[0066] Formula (D) is the structure of compound 2; Formula (E) is the main 1 H- 1 H COSY and HMBC correlation; Formula (F) is the main NOE correlation of compound 2.
[0067] Preliminary analysis found that the NMR data of compound 2 and neoabietic acid (J.Appl.Spectrosc.,2008,75,439-443) are very similar. The difference between the two is that the group of methylene signals in neoabietic acid [(δ C 26.5); (δ H 1.84,m,H a -12); (δ H 2.54,m,H b -12)] is replaced by a group of oxygen-linked methine signals in compound 2 [(δC 73.6); (δ H 4.35)] and compound 2 has one more methoxy signal. In the HMBC spectrum of compound 2 (Formula V), the oxygen-linked methine protons (δ H 4.35) and C-9 (δ C 46.9), C-11(δ C 26.9), C-13(δ C 127.8), C-14(δ C 119.5), C-15(δ C 128.9), indicating that the oxymethyl group is located at the C-12 position. H 4.35) / H b -11(δ H 2.07) and H b -11(δ H 2.07) / H-9(δ H 2.12) 1 H- 1 The H COSY related signal further confirmed that the oxymethyl group was located at the C-12 position. H 3.26) and C-12 (δ C 73.6), and the methoxy group was inferred to be located at the C-21 position based on the molecular formula and mass spectrometry data. By comprehensively analyzing the two-dimensional spectrum of compound 2, its planar structure was finally determined to be a rosinane-type diterpene with a conjugated double bond in the C ring.
[0068] The stereo configuration of compound 2 was determined mainly by NOESY spectrum analysis, electronic circular dichroism (ECD) and quantum chemical calculation. In abietane-type diterpenes, the A / B rings are trans-coupled, that is, H-5 is in α configuration and Me-20 is in β configuration. In the NOESY spectrum of compound 2 (Formula VI), it can be observed that Me-20 (δ H 0.76) / Me-19(δ H 1.19), suggesting that Me-19 is in β configuration. H 4.35) / H a -11(δ H 1.32) and H a -11(δ H 1.32) / Me-20(δ H 0.76), but no NOE correlation signal exists between H-11 and H-12, indicating that H-12 is of β configuration. H 2.13) / H-5(δH 2.01), indicating that H-9 is in α configuration. In order to further determine the configuration of the chiral center at C-12 of compound 2, we performed NMR calculations on its two possible relative configurations at the B3LYP / 6-311G(d,p) level, and determined the relative configuration of C-12 by performing DP4+ feasibility analysis on the theoretical and measured values. The results of DP4+ probability test analysis showed that the proportion of (4R*,5R*,9S*,10R*,12S*)-2(Isomer 1) was 100%, indicating that compound 2 and Isomer 1 have the same relative configuration, namely 4R*,5R*,9S*,10R*,12S*.
[0069] In order to determine the absolute configuration of compound 2, we conducted ECD tests and calculations, and compared the calculated ECD spectrum with the experimental spectrum. The results showed that the calculated ECD spectrum of (4R, 5R, 9S, 10R, 12S)-2 showed a positive cotton effect at wavelengths of 211 and 247nm, which was consistent with the measured spectrum, so the absolute configuration of compound 2 was determined to be 4R, 5R, 9S, 10R, 12S. Given the above analysis, compound 2 was resolved to have the structure shown in formula (II) and was named TorregrandinL.
[0070] Table 2 NMR data of compound 2 (CDCl3; hydrogen spectrum and carbon spectrum were measured at 400 and 100 MHz respectively)
[0071]
[0072] Example 3 Evaluation of the in vitro anti-inflammatory activity of the compounds
[0073] 1. RAW 264.7 cells in the logarithmic growth phase (purchased from Wuhan Sean Biotechnology Co., Ltd.) were prepared into a single-cell suspension using DMEM (Dulbecco's Modified Eagle Medium) culture medium. After counting, 200,000 cells / well were inoculated into a 12-well plate and cultured in a 37°C, 5% CO2 cell culture incubator until the cell density reached 80%, and the supernatant was discarded; a blank group (control), a lipopolysaccharide inflammation model group (model), a positive drug control group (Dexamethasone, DEX) and a sample group were set up.
[0074] The blank group was added with 2 mL of DMEM medium; the LPS inflammation model group was added with 1 μM LPS at the final concentration on the basis of the blank group; the sample group was added with 1, 3, 9 μM compound 1 or 2 at the final concentration on the basis of the model group; the positive drug control group was added with 1 μM DEX at the final concentration on the basis of the model group, and 3 parallel wells were set for each concentration, and the adherent culture was continued for 24 hours. The medium was discarded and the cells were collected.
[0075] 2. Place the 12-well plate with the culture medium discarded on ice, add 0.5 mL Trizol lysis buffer to each well, lyse for 10 minutes, blow down the cells with a gun tip, transfer to a 1.5 mL EP tube, let stand for 5 minutes, then add 200 μL chloroform, vortex until pink, let stand for 5 minutes, and centrifuge at 12000 rpm and 4°C for 15 minutes. Carefully take 100 μL supernatant (aqueous phase) and transfer to a new EP tube. Add an equal volume of isopropanol to the EP tube, mix well, let stand for 10 minutes, centrifuge at 12000 rpm and 4°C for 10 minutes, at which time a trace of white colloid can be observed at the bottom of the EP tube. Discard the supernatant, add 1 mL of 75% ethanol to suspend the precipitate, let stand for 5 minutes, centrifuge at 12000 rpm and 4°C for 5 minutes, discard the supernatant, dry at room temperature for 10 minutes, and obtain mRNA. Add 15 μL of sterile enzyme-free water to fully dissolve the mRNA, and use the Thermo Nanordrop 2000 nucleic acid protein analyzer to measure the mRNA concentration.
[0076] 3. According to the instructions of the TaKaRa reverse transcription kit, reverse transcribe the mRNA into cDNA. The synthesized cDNA can be directly used for qPCR or stored in a -80℃ refrigerator.
[0077] 4. Real-time fluorescence quantitative PCR (quantitative real-time PCR, qPCR) method uses 20μL system qPCR. The reaction system is Hieff qPCR SYBR Green Master Mix 10μL, forward primer 0.4μL, reverse primer 0.4μL (primer sequence see Table 3), sterile enzyme-free water 8.2μL, and cDNA 1μL of the sample to be tested. The reaction conditions of the Real-Time PCR instrument are set to 95℃5min pre-denaturation, and 95℃10s, 60℃30s for 40 consecutive cycles. After the reaction is completed, use 2 -△△Ct Methods The relative expression of mRNA was calculated and the results were imported into Graphpad Pism9.5 software. One-way ANOVA was used for hypothesis testing. p<0.05 was considered statistically significant.
[0078] 5. Evaluation results of anti-inflammatory activity of compounds 1 and 2
[0079] In order to study whether compounds 1 and 2 of the present invention can inhibit the mRNA expression level of inflammatory factors in RAW 264.7 cells induced by LPS, the RT-qPCR method was used to detect the mRNA expression levels of inflammatory factors IL-1β and IL-6 in macrophages 24 hours after administration of samples of different concentrations. Fig.10 and Fig.24 The results showed that compared with the control group, the model group could significantly upregulate the mRNA expression of inflammatory factors IL-1β and IL-6 under the stimulation of LPS, and the expression levels were 59 times and 228 times of the control group, respectively, with significant differences (P<0.0001), indicating that the inflammatory model was successfully established. Compared with the model group, DEX administration 24 hours later could significantly downregulate the mRNA expression of inflammatory factors IL-1β and IL-6, with significant differences (P<0.0001). After treating macrophages with different concentrations of compounds 1 and 2 for 24 hours, the mRNA expression of inflammatory factors IL-1β and IL-6 could be significantly downregulated. Compared with the model group, low (1μM), medium (3μM), and high (9μM) concentrations of compound 1 reduced the expression of IL-1β mRNA by 12.19%, 22.43%, and 37.58%, respectively, and reduced the expression of IL-6 mRNA by 30.27%, 36.49%, and 36.88%, respectively. The low (1 μM), medium (3 μM), and high (9 μM) concentrations of compound 2 reduced the expression of IL-1β mRNA by 35.87%, 37.15%, and 46.26%, respectively, and reduced the expression of IL-6 mRNA by 31.79%, 45.07%, and 45.66%, respectively.
[0080] The above results show that in the LPS-induced RAW 264.7 cell inflammation model, compounds 1 and 2 involved in the present invention have a good inhibitory effect on the expression of inflammatory factors IL-1β and IL-6 mRNA, and can reduce the LPS-induced inflammatory response in RAW264.7 cells in a dose-dependent manner, and are expected to provide a lead structure for the development of new anti-inflammatory drugs.
[0081] Table 3 qPCR primer sequences
[0082]
Claims
1. A rosinane-type diterpenoid compound, the structural formula of which is shown in formula (I); 2. A method for preparing the abietane-type diterpenoid compound according to claim 1, characterized in that: The method is carried out according to the following steps: 1) taking Torreya grandis aril, drying naturally, crushing, extracting with an organic solvent, and recovering the solvent under reduced pressure to obtain a crude extract; the organic solvent is 95% ethanol, methanol or acetone; 2) suspending the crude extract with water, extracting with an organic solvent, collecting the organic phase, and recovering the solvent under reduced pressure to obtain an extract; the organic solvent is petroleum ether, ethyl acetate, dichloromethane or chloroform; 3) dissolving the extract from step 2) in methanol, and performing gradient elution on an MCI CHP20P column using methanol / water in a volume ratio of 10:90 to 100:0 as an eluent, with 4 column volumes for each gradient elution, and performing thin layer chromatography detection using dichloromethane / methanol in a volume ratio of 20:1, and collecting components with Rf values of 0.4-0.5 and 0.5-0.6 respectively; 4) The component with an Rf value of 0.5-0.6 obtained in step 3) was dissolved in methanol and then subjected to gradient elution on a silica gel column using a petroleum ether / acetone mixed solvent with a volume ratio of 6:1 to 3:1 as an eluent, with each gradient elution lasting 4 column volumes, and thin layer chromatography detection was performed with dichloromethane / methanol with a volume ratio of 20:1, and the component with an Rf value of 0.5 was collected; finally, the component with an Rf value of 0.5 was purified by semi-preparative liquid chromatography using methanol / water with a volume ratio of 65:35 as a mobile phase, and the component with a retention time of 14 min was collected, and the solvent was removed by concentrating under reduced pressure to obtain the compound represented by formula (I).
3. The preparation method according to claim 2, characterized in that In step 1), the volume amount of the organic solvent is 2-5 mL / g based on the weight of the Torreya grandis aril powder; the extraction is performed at least 3 times, and each extraction time is 3-5 days.
4. The preparation method according to claim 2, characterized in that: In step 2), the volume of water used is 2-5 mL / g based on the weight of the crude extract; the volume ratio of the organic solvent to water is 1:0.5-2; and the extraction is performed 3-5 times.
5. The preparation method according to claim 2, characterized in that: In step 3), the elution conditions of the MCI CHP20P column chromatography are: gradient elution using a methanol / water mixed solvent with a volume ratio of 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, and 100:0 as the eluent.
6. The preparation method according to claim 2, characterized in that: In step 4), the elution conditions of the silica gel column chromatography are: gradient elution using a petroleum ether / acetone mixed solvent with a volume ratio of 6:1, 4:1, and 3:1 as the eluent.
7. Use of the abietane-type diterpenoid compound according to claim 1 in the preparation of an inflammatory factor inhibitor.
8. The use according to claim 7, characterized in that The inflammatory factor is IL-1β or IL-6.
9. Use of the abietane-type diterpenoid compound according to claim 1 in the preparation of anti-inflammatory drugs.
